April 27, 2010
Asahi Kasei Pharma Corp.

Preliminary Results of Phase III clinical study of AT-877 for acute cerebral infarction
 
Asahi Kasei Pharma has unblinded the data from a Phase III clinical study of AT-877 (fasudil hydrochloride hydrate) for acute cerebral infarction. Preliminary analysis indicates that the study's primary efficacy endpoint was not met.

Asahi Kasei Pharma will perform a detailed analysis of the results of this study and make a final decision regarding the possibility for further clinical development of fasudil hydrochloride hydrate for acute cerebral infarction.
 
Note: Fasudil hydrochloride hydrate is sold as Eril™ injection 30 mg for cerebral vasospasm and associated cerebral ischemic symptoms following surgery for subarachnoid hemorrhage (SAH).
 
 
 
 
 

Back to press release list

News

Adobe Readeris required to view these PDF files.

page top